Datwyler Invests in Delaware Plant
The company invested more than CHF 100 million in a new Delaware manufacturing plant.
On Oct. 11, 2016, Datwyler announced that it is investing more than CHF 100 million (approximately $101 million) in a new manufacturing plant in Delaware, US. The new plant will be used to manufacture elastomer components for injectable drug delivery systems. The company said construction on the new plant will most likely begin before the end of 2016, with production scheduled to begin in the first half of 2018. The plant is expected to provide jobs for approximately 120 employees. In a press announcement, the company said that this new plant will strengthen Datwyler’s position in the US market. The new plant will serve customers in three key business regions, the US, Europe, and Asia.
Source: Datwyler
Biotech EG 427 Raises €27 Million in Series B Funding to Advance Lead Genetic Medicine Candidate
February 24th 2025Co-led by Andera Partners and Bpifrance, the Series B financing will go toward an ongoing Phase Ib/IIa clinical study for EG 427’s lead candidate and to advance the company’s genetic medicines platform.
